P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine

Pathology and Oncology Research

Volumn 11, Issue 3, 2005, Pages 164-169

  Zalatnai, Attila ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Human tumors; Mimosine; P glycoprotein; Pancreatic cancer; Xenografts

Indexed keywords

GLYCOPROTEIN P; KI 67 ANTIGEN; MIMOSINE; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MITOSIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

EID: 27644510512     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893393     Document Type: Article

References (41)

1. Abe S, Kubota T, Otani Y, et al: UCN-01 (7-hydroxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery. Jpn J Cancer Res 92: 537-545, 2001.
2. Abolhoda A, Wilson AE, Ross H, et al: Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5: 3352-3356. 1999.
3. Bocsi J, Zalatnai A: Establishment and long term xenografting of human pancreatic carcinomas in immunosuppressed mice: Changes and stability in morphology, DNA ploidy and proliferative activity. J Cancer Res Clin Oncol 125: 9-19, 1999.
4. Buolamwini JK: Cell cycle molecular targets in novel anti-cancer drug discovery. Curr Pharm Des 6: 379-392, 2000.
5. Chang HC, Lee TH, Chuang LY, et al: Inhibitory effect of mimosine on proliferation of human lung cancer cells is mediated by multiple mechanisms. Cancer Lett 145: 1-8, 1999.
6. Chang HC, Weng CF, Yen MH, et al: Modulation of cell cycle regulatory protein expression and suppression of tumor growth by mimosine in nude mice. Int J Oncol 17: 659-665, 2000.
7. Chaudhry PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632-639, 1993.
8. Chung HC, Rha SY, Kim JH, et al: P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 42: 65-72, 1997.
9. Fardel O, Lecureur V, Daval S, et al: Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 246: 186-192, 1997.
10. Feldman ST, Schönthal A: Negative regulation of histone H1 kinase expression by mimosine, a plant amino acid. Cancer Res 54: 494-498, 1994.
11. Goldstein LJ, Galski H, Fojo A, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989.
12. Granzotto M, Drigo I, Candussio L, et al: Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. Cancer Lett 205: 107-115, 2004.
13. Jimenez RE, Zalupski MM, Frank JJ, et al: Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 86: 976-981, 1999.
14. Krude T: Mimosine arrests proliferating human cells before onset of DNA replication in a dose-dependent manner. Exp Cell Res 247: 148-159, 1999.
15. Lage H, Dietel M: Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J Cancer Res Clin Oncol 128: 349-357, 2002.
16. Leonard GD, Fojo T, Bates SE: The role of ABC transporters in clinical practice. Oncologist 8: 411-424, 2003.
17. Licht T, Fiebig HH, Bross KJ, et al: Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer 49: 630-637, 1991.
18. Lu Z, Kleeff J, Shrikhande S, et al: Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 21: 240-247, 2000.
19. Mealey KL, Barhoumi R, Burghardt RC, et al: Doxycycline induces expression of P glycoprotein in MCF-7 breast carcinoma cells. Antimicrob Agents Chemother 46: 755-761, 2002.
20. Monden N, Abe S, Hishikawa Y, et al: The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy. Int J Surg Invest 1: 3-10, 1999.
21. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ: The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3: 59-70, 2004.
22. Ng IO, Lam KY, Ng M, et al: Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma. Cancer 83: 851-857, 1998.
23. Nielsen D, Eriksen J, Maare C, et al. P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin. Br J Cancer 78: 1175-1180, 1998.
24. Owa T, Yoshino H, Yoshimatsu K, Nagasu T: Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 8: 1487-1503, 2001.
25. Ruiz van Haperen VW, Veerman G, Eriksson S, et al. Induction of resistance to 2′, 2′-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Semin Oncol 22(Suppl 11): 35-41, 1995.
26. Sandor V, Bakke S, Robey RW, et al: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718-728, 2002.
27. Sandor V,Robbins AR, Robey R, et al. FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anti-cancer Drugs 11: 445-545, 2000.
28. Sato N, Ohta T, Kitagawa H, et al: FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 24: 679-685, 2004.
29. Schondorf T, Neumann R, Benz C, et al: Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Recent Results Cancer Res 161: 111-116, 2003.
30. Sun D, Urrabaz R, Buzello C, Nguyen M: Induction of DNA ligase I by 1-beta-D-arabinosylcytosine and aphidicolin in Mia-PaCa human pancreatic cancer cells. Exp Cell Res 280: 90-96, 2002.
31. Suwa H, Ohshio G, Arao S, et al: Inimunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Jpn J Cancer Res 87: 641-649, 1996.
32. Thomas H, Coley HM: Overcoming multidrug resistance in cancer: an update on clinical strategy on inhibiting P-glycoprotein. Cancer Control 10: 159-165, 2003.
33. Tomida A, Naito M, Tsuruo T: Acute induction of adriamycin-resistance in human colon carcinoma HT-29 cells exposed to a sublethal dose of adriamycin. Jpn J Cancer Res 86: 224-232, 1995.
34. Tsvetkov LM, Russev GC, Anachkova BB: Effect of mimosine on DNA synthesis in mammalian cells. Cancer Res 57: 2252-2255, 1997.
35. Wada M, Hosotani R, Lee JU, et al: An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl2 ratio in p53-mutated pancreatic cancer cells. Anti-cancer Res 18: 2559-2566, 1998.
36. Wang G, Miskimins R, Miskimins WK: Mimosine arrests cells in G1 by enhancing the levels of p27(Kip1). Exp Cell Res 254: 64-71, 2000.
37. Wartenberg M, Fischer K, Hescheler J, Sauer H: Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors. Biochim Biophys Acta 1589: 49-62, 2002.
38. Watson PA, Hanauske-Abel HH, Flint A, Lalande M: Mimosine reversibly arrests cell cycle progression at the G1-S phase border. Cytometry 12: 242-246, 1991.
39. Zalatnai A: Epidermal growth factor receptor, somatostatin and bcl-2 in human pancreatic tumor xenografts. An immunohistochemical study. Pathol Oncol Res 5: 146-151, 1999.
40. Zalatnai A: Potential role of cell cycle synchronizing agents in combination treatment modalities of malignant tumors. In vivo 19: 85-91, 2005.
41. Zalatnai A, Bocsi J: Mimosine, a plant-derived amino acid induces apoptosis in human pancreatic cancer xenografts. Anti-cancer Res 23: 4007-4010, 2003.